Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 34, Issue 14, 2016, Pages 1652-1659

  Halabi, Susan ^a   Kelly, William Kevin ^b   Ma, Hua ^a   Zhou, Haojin ^c   Solomon, Nicole C ^a   Fizazi, Karim ^d   Tangen, Catherine M ^e   Rosenthal, Mark ^f   Petrylak, Daniel P ^g   Hussain, Maha ^h   Vogelzang, Nicholas J ⁱ   Thompson, Ian M ^j   Chi, Kim N ^l   De Bono, Johann ⁿ   Armstrong, Andrew J ^a   Eisenberger, Mario A ^o   Fandi, Abderrahim ^p   Li, Shaoyi ^p   Araujo, John C ^k   Logothetis, Christopher J ^k   Quinn, David I ^q   Morris, Michael J ^t   Higano, Celestia S ^s   Tannock, Ian F ^m   Small, Eric J ^r   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g YALE CANCER CENTER   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ US Oncology ^*  (United States)

^j UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p CELGENE CORPORATION   (United States)

^q UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF WASHINGTON   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; META ANALYSIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; AGED; BONE TUMOR; LIVER TUMOR; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

AGED; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84971006454     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.7270     Document Type: Article

References (27)

1. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003.
2. Armstrong AJ, Garrett-Mayer ES, Yang YC, et al: A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 13: 6396-6403, 2007.
3. Kelly WK, Halabi S, Carducci MA, et al: Liver metastases predict for shorter overall survival in metastatic castration-resistant prostate cancer. J Clin Oncol 30, 2012 (suppl; abstr 4655).
4. Halabi S, Lin CY, Small EJ, et al: Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 105: 1729-1737, 2013.
5. Halabi S, Lin CY, Kelly WK, et al: Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32: 671-677, 2014.
6. Templeton AJ, Pezaro C, Omlin A, et al: Simple prognostic score for metastatic castrationresistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 120: 3346-3352, 2014.
7. Pond GR, Sonpavde G, de Wit R, et al: The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 65:3-6, 2014.
8. Loriot Y, Fizazi K, de Bono JS, et al: Outcomes in patients with liver or lung metastatic castrationresistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFRIRM trial. J Clin Oncol 31, 2013 (suppl; abstr 5065).
9. Chi KN, Kheoh TS, Ryan CJ, et al: A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. J Clin Oncol 31, 2013 (suppl; abstr 5015).
10. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004.
11. Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004.
12. Scher HI, Jia X, Chi K, et al: Randomized, openlabel phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29:2191-2198, 2011.
13. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012.
14. Fizazi K, Higano CS, Nelson JB, et al: Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740-1747, 2013 [erratum: J Clin Oncol 32: 3461, 2013].
15. Quinn DI, Tangen CM, Hussain M, et al: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial. Lancet Oncol 14:893-900, 2013.
16. Tannock IF, Fizazi K, Ivanov S, et al; VENICE Investigators: Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castrationresistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol 14: 760-768, 2013.
17. Araujo JC, Trudel GC, Saad F, et al: Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial. Lancet Oncol 14:1307-1316, 2013.
18. Petrylak DP, Vogelzang NJ, Budnik N, et al: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 16:417-425, 2015.
19. Chi KN, Higano CS, Blumenstein BA, et al: Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) cancer with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. J Clin Oncol 33, 2015 (suppl; abstr 5009).
20. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986.
21. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665-1677, 1991.
22. Pezaro CJ, Omlin A, Lorente D, et al: Visceral disease in castration-resistant prostate cancer. Eur Urol 65:270-273, 2014.
23. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008.
24. Ryan CJ, Smith MR, de Bono JS, et al; COUAA- 302 Investigators: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013.
25. Beer TM, Armstrong AJ, Rathkopf DE, et al; PREVAIL Investigators: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014.
26. Fizazi K, Jones R, Oudard S, et al: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxelbased therapy: ELM-PC 5. J Clin Oncol 33: 723-731, 2015.
27. Scher HI, Morris MJ, Stadler W, et al: Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group (PCWG3). J Clin Oncol, (in press).